Article Information
History
- August 22, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Tilman Lingscheid1,
- Martina Kinzig2,
- Anne Krüger3,
- Nils Müller3,
- Georg Bölke3,
- Pinkus Tober-Lau1,
- Friederike Münn1,
- Helene Kriedemann1,
- Martin Witzenrath1,4,
- Leif E. Sander1,4,5,
- Fritz Sörgel2,6,# and
- Florian Kurth1,7,#,*
- 1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Infectious Diseases and Respiratory Medicine, Augustenburger Platz 1, 13353 Berlin, Germany
- 2IBMP – Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Straße 19, 90562, Nürnberg-Heroldsberg, Germany
- 3Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Nephrology and Intensive Care, Augustenburger Platz 1, 13353 Berlin, Germany
- 4German Center for Lung Research, DZL, Berlin, Germany
- 5Berlin Institute of Health, Berlin, Germany
- 6Institute of Pharmacology, West German Heart and Vascular Centre, University of Duisburg-Essen, 45147 Essen, Germany
- 7Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Straße 74, 20359 Hamburg, Hamburg, Germany
- ↵*Correspondence to:
florian.kurth{at}charite.de
↵# contributed equally
Posted August 22, 2022.
Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with end stage renal disease on intermittent haemodialysis
